Last updated: February 19, 2026
NEUPOGEN (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) used to prevent and treat neutropenia, a condition characterized by low white blood cell counts, particularly in patients undergoing chemotherapy or bone marrow transplantation. Its market performance and future trajectory are influenced by patent expiries, biosimilar competition, and evolving healthcare reimbursement policies.
What is NEUPOGEN's Current Market Position?
NEUPOGEN, originally developed by Amgen, held a dominant position in the G-CSF market for decades. As a first-mover, it established a significant market share and brand recognition. However, the landscape has shifted considerably with the advent of biosimil versions.
- Originator Drug: NEUPOGEN (filgrastim)
- Developer: Amgen
- Mechanism of Action: Stimulates the production, maturation, and release of neutrophils from bone marrow.
- Primary Indications:
- Reduction in the incidence of febrile neutropenia, neutropenia, and febrile neutropenia associated with chemotherapy in patients with malignancies.
- Reduction in the duration of neutropenia and the incidence of febrile neutropenia, mucositis, fever, and hospitalization due to infection in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.
- Mobilization of peripheral blood progenitor cells (PBPCs) for autologous or allogeneic transplantation.
- Chronic administration to reduce the incidence and duration of neutropenia in patients with severe chronic neutropenia (SCN).
- Market Share Erosion: The introduction of biosimil filgrastim has led to significant price competition and a decline in NEUPOGEN's market share. Biosimil manufacturers leverage lower production costs and aggressive pricing strategies to capture market segments.
- Geographic Penetration: NEUPOGEN has been globally marketed, with substantial presence in North America, Europe, and other major pharmaceutical markets. Biosimilar availability varies by region, impacting the pace of market share shift.
What is the Patent Expiry and Biosimilar Landscape for NEUPOGEN?
The patent protection for NEUPOGEN has largely expired, paving the way for biosimilar development and market entry. This has fundamentally altered the competitive environment and pricing dynamics.
- Original Patents: Amgen’s foundational patents for NEUPOGEN have long expired.
- Key Biosimilar Entrants:
- Zarxio (filgrastim-sndz): The first filgrastim biosimilar approved in the United States by Sandoz (Novartis) in March 2015.
- Granix (filgrastim): Approved by Teva Pharmaceuticals.
- Nivestim (filgrastim): Developed by Pfizer (following its acquisition of Hospira).
- Eficibate (filgrastim): Developed by Samsung Bioepis.
- Fylnetra (filgrastim-aumh): Developed by Amneal Pharmaceuticals.
- Impact on Pricing: Biosimilar entry has driven down the average selling price (ASP) of filgrastim. Studies indicate that biosimilar filgrastim has achieved substantial discounts compared to the originator product. For example, in the US, discounts of 10-30% for biosimil filgrastim have been reported in certain market segments shortly after launch.
- Interchangeability Status: The designation of interchangeability for biosimil filgrastim is crucial for market penetration. An interchangeable biosimilar can be substituted for the reference product by a pharmacist without the intervention of the prescriber. While some filgrastim biosimil products are approved for interchangeability in the U.S., this status can vary and impacts prescriber and payer adoption.
- European Market: Europe has a more established biosimilar market. Filgrastim biosimil products have been available and widely adopted for a longer period, leading to significant price reductions.
How Has NEUPOGEN's Financial Performance Evolved?
NEUPOGEN was a significant revenue generator for Amgen. Its financial trajectory has been marked by strong initial growth followed by a predictable decline due to biosimilar competition.
- Peak Sales: NEUPOGEN achieved peak annual sales exceeding $3 billion for Amgen.
- Revenue Decline: Following the introduction of biosimil filgrastim, Amgen has reported a consistent decline in NEUPOGEN sales.
- In 2017, Amgen reported NEUPOGEN sales of approximately $1.3 billion.
- By 2022, NEUPOGEN sales had fallen to approximately $666 million.
- Q1 2023 sales were reported at approximately $150 million.
- Biosimilar Impact: The erosion in sales is directly attributable to the price pressure exerted by biosimilar filgrastim products in both the US and international markets.
- Amgen's Strategy: Amgen has focused on its newer, more advanced biosimilar products and differentiated biologic therapies to offset the decline in NEUPOGEN revenue. They also introduced their own biosimilar filgrastim, Amjevita (adalimumab), though this is a different molecule and not a biosimilar of NEUPOGEN. Amgen also has its own biosimilar filgrastim product, ABP 957, which was approved in Europe.
- Market Value of Filgrastim: The global market for filgrastim, encompassing both originator and biosimilar products, has seen significant growth driven by increasing cancer incidence and the broader adoption of biosimil therapies. However, the value of the originator product has decreased.
What are the Key Market Access and Reimbursement Considerations?
Market access and reimbursement policies play a critical role in the uptake of NEUPOGEN and its biosimil competitors. Payers and healthcare providers are influenced by cost-effectiveness and formulary placement.
- Payer Strategies: Health insurance companies and government payers (e.g., Medicare, Medicaid) are actively managing the G-CSF market through formulary design, prior authorization requirements, and preferred drug lists.
- Biosimilar Uptake Incentives: Payers often incentivize the use of biosimil filgrastim by placing them on preferred tiers with lower co-pays for patients or by offering rebates to providers for prescribing biosimil versions.
- Provider Adoption: Physician prescribing patterns are influenced by clinical trial data, ease of administration, familiarity with the product, and reimbursement status. The availability of interchangeable biosimil filgrastim can accelerate adoption by reducing administrative burden.
- Value-Based Purchasing: As healthcare systems move towards value-based care models, the cost-effectiveness of G-CSF therapy becomes paramount. Biosimil filgrastim generally offers a more favorable cost-effectiveness profile compared to the originator product.
- Pharmacy Benefit Managers (PBMs): PBMs negotiate drug prices and rebates on behalf of health plans, significantly influencing which G-CSF products are favored on formularies.
What are the Future Market Projections for NEUPOGEN?
The future market for NEUPOGEN is characterized by continued pressure from biosimil competition and a shrinking share of the overall G-CSF market.
- Continued Biosimilar Growth: The market share of biosimilar filgrastim is expected to continue to increase globally. This is driven by expanding indications, favorable reimbursement, and increased physician confidence.
- Price Compression: The ASP for filgrastim is projected to remain depressed due to ongoing competition among multiple biosimilar manufacturers.
- Amgen's Strategic Focus: Amgen will likely continue to de-emphasize NEUPOGEN and focus its resources on its portfolio of newer biologics and biosimil products.
- Emerging Markets: The penetration of biosimilar filgrastim in emerging markets is expected to accelerate, further contributing to the decline of originator NEUPOGEN sales in those regions.
- Newer Therapies: While NEUPOGEN and its biosimil counterparts remain the standard of care for many neutropenia indications, ongoing research in supportive care for cancer patients may introduce novel therapeutic approaches that could eventually impact the market. However, G-CSF therapy is well-established and cost-effective, making significant disruption unlikely in the short to medium term.
Key Takeaways
- NEUPOGEN's market dominance has been irrevocably altered by patent expiry and the subsequent introduction of multiple filgrastim biosimil products.
- Biosimilar filgrastim has driven substantial price reductions and eroded NEUPOGEN's market share and revenue for originator Amgen.
- Market access and reimbursement strategies by payers and PBMs are crucial in dictating the uptake of both originator and biosimilar filgrastim.
- The future trajectory of NEUPOGEN points to continued market share decline, with biosimil filgrastim expected to capture an increasing majority of the G-CSF market globally.
Frequently Asked Questions
-
What is the primary therapeutic advantage of NEUPOGEN over its biosimil versions?
NEUPOGEN is the originator product and has a long established clinical track record. However, biosimilar filgrastim products are demonstrated to be highly similar in terms of safety, efficacy, and quality. The primary advantage of biosimil versions is their significantly lower cost.
-
How does the regulatory approval pathway for biosimil filgrastim differ from that of the originator NEUPOGEN?
The approval pathway for biosimil filgrastim involves demonstrating high similarity to the reference product (NEUPOGEN) through analytical, pharmacokinetic, and pharmacodynamic studies, as well as clinical efficacy and safety data. This differs from the initial drug development and approval of NEUPOGEN, which required extensive de novo clinical trials.
-
Are there any specific patient populations where NEUPOGEN is still strongly preferred over biosimil filgrastim?
While biosimilar filgrastim is widely adopted, physician preference and established treatment protocols for specific patient populations or complex cases can sometimes lead to continued use of the originator. However, this is increasingly rare due to the clinical interchangeability and cost benefits of biosimil versions.
-
What is the typical discount range observed for filgrastim biosimil products compared to NEUPOGEN?
Discounts for filgrastim biosimil products typically range from 10% to over 50%, depending on the specific biosimilar, market, contracting agreements, and the volume of product purchased.
-
Will Amgen continue to market NEUPOGEN indefinitely, or is there a point at which they might discontinue the product?
Amgen is likely to continue marketing NEUPOGEN as long as it remains commercially viable, even with declining sales. However, as biosimilar competition intensifies and sales fall below a profitable threshold, discontinuation becomes a possibility. Amgen's focus has shifted to newer therapies and biosimilar products.
Citations
[1] Amgen. (n.d.). NEUPOGEN® (filgrastim) prescribing information. Retrieved from [Relevant prescribing information source, e.g., manufacturer's website or FDA database – specific URL would be needed for a live document].
[2] Sandoz. (n.d.). Zarxio® (filgrastim-sndz) prescribing information. Retrieved from [Relevant prescribing information source, e.g., manufacturer's website or FDA database].
[3] U.S. Food and Drug Administration. (2015, March 6). FDA approves Zarxio, the first biosimilar approved in the United States. FDA News Release.
[4] Various pharmaceutical market analysis reports (e.g., IQVIA, Evaluate Pharma, GlobalData) that track drug sales and market share for NEUPOGEN and filgrastim biosimil products. (Specific report details and dates would be necessary for precise citation).
[5] Annual and quarterly financial reports of Amgen Inc. (Specific report titles and dates would be necessary for precise citation, e.g., Amgen Inc. (2023). Q1 2023 Earnings Release).
